A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-18 and is reviewed periodically as new material appears.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
This is a list of investigational sleep apnea drugs, or drugs that are currently under development for clinical use in the treatment of sleep apnea but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
On 26 August 2008, Michael Totten published the report which contained an interview with an expert Patrick Worms who worked in Tbilisi. Worms's version of events was confirmed by an academic Thomas Goltz. Worms said: "The Ossetians start provoking and provoking and provoking by shelling Georgian positions and Georgian villages around there. And it's a classic tit for tat thing. You shell, I shell back. The Georgians offered repeated ceasefires, which the Ossetians broke. (...) On the 6th of August the shelling intensifies from Ossetian positions. And for the first time since the war finished in 1992, they are using 120mm guns. (...) Because of the peace agreement they had, nobody was allowed to have guns bigger than 80mm. Okay, so that's the formal start of the war. It wasn't the attack on Tskhinvali." In August 2008, Peter Roudik, Senior Foreign Law Specialist working for the Library of Congress, criticized Russian claim that the Georgian attack on Tskhinvali was "an act of aggression" and that the aim of Russian intervention was defence against the Georgian forces, saying that only the United Nations Security Council can identify an act of aggression after studying the causes of the military actions. He pointed out that "an act of aggression requires use of the armed forces of a state against the sovereignty, territorial integrity, or political independence of another state," and that South Ossetia was a part of Georgia on 8 August 2008. This reasoning for Russia's action was questionable since there was no "possibility of Georgian aggression against South Ossetia".
== Treatment == This applies once an infestation is established. In many circles the first response to cutaneous myiasis once the breathing hole has formed is to cover the air hole thickly with petroleum jelly. Lack of oxygen then forces the larva to the surface, where it can more easily be dealt with. In a clinical or veterinary setting there may not be time for such tentative approaches, and the treatment of choice might be more direct, with or without an incision. First, the larva must be eliminated through pressure around the lesion and the use of forceps. Secondly, the wound must be cleaned and disinfected. Further control is necessary to avoid further reinfestation. Livestock may be treated prophylactically with slow-release boluses containing ivermectin, which can provide long-term protection against the development of the larvae. Sheep also may be dipped, a process that involves drenching the animals in persistent insecticide to poison the larvae before they develop into a problem.
In 2021, Pansino hosted the HBO Max series Baketopia where contestants competed in a bake-off to win up to $10,000; her hosting work on the show received praise and she also executive produced several episodes. In November 2024, Pansino started her own podcast series called the "Rodiculous Podcast", where she has interviews and conversations with celebrities and fellow YouTubers, with a lot of them being her friends.
There are no definite historical records concerning the particular shroud currently at Turin Cathedral prior to the 14th century. A burial cloth, which some historians maintain was the Shroud, was owned by the Byzantine emperors but disappeared during the Sack of Constantinople in 1204. Although there are numerous reports of Jesus's burial shroud, or an image of his head, of unknown origin, being venerated in various locations before the 14th century, there is no historical evidence that these refer to the shroud currently in Turin. In 1353 the village of Lirey, in north-central France, was enriched with a small collegiate church endowed by the local feudal lord, a knight named Geoffroi de Charny. Charny died in 1356 at the Battle of Poitiers. Around 1355, the dean of the chapter of Lirey, Robert de Caillac, began exhibiting in the church a long fabric that bore an image of the mangled body of Jesus. Nicole Oresme, the Bishop of Lisieux, denounced the shroud as a forgery, believing it to be the work of clergymen for the purpose of making money for their churches. In 1390 the Bishop of Troyes, Pierre d'Arcis, who had jurisdiction over the church in Lirey, wrote a lengthy memorandum to Antipope Clement VII (recognized as Pope by the Church in France during the Western Schism), declaring that the Shroud was a forgery and that a previous Bishop of Troyes, Henri de Poitiers, had identified the artist who had made it.
Sources: en.wikipedia.org
As a consequence of the September 11 attacks, American forces immediately increased their readiness to the highest level in 28 years, closing the blast doors of the NORAD's Cheyenne Mountain Operations Center for the first time due to a non-exercise event. But unlike similar increases during the Cold War, Russia immediately decided to stand down a large military exercise in the Arctic region, in order to minimize the risk of incidents, rather than following suit. The former chair of the United Nations disarmament committee stated that there are more than 16,000 strategic and tactical nuclear weapons ready for deployment and another 14,000 in storage, with the U.S. having nearly 7,000 ready for use and 3,000 in storage, and Russia having about 8,500 ready for use and 11,000 in storage. In addition, China is thought to possess about 400 nuclear weapons, Britain about 200, France about 350, India about 80–100, and Pakistan 100–110. North Korea is confirmed as having nuclear weapons, though it is not known how many, with most estimates between 1 and 10. Israel is also widely believed to possess usable nuclear weapons. NATO has stationed about 480 American nuclear weapons in Belgium, the Netherlands, Italy, Germany, and Turkey, and several other nations are thought to be in pursuit of an arsenal of their own. Pakistan's nuclear policy was significantly affected by the 1965 war with India. The 1971 war and India's nuclear program played a role in Pakistan's decision to go nuclear. India and Pakistan both decided not to participate in the NPT.
=== Wnt signaling === In 2012, Garcia's laboratory determined the crystal structure of a Wnt protein in complex with its cellular receptor, Frizzled. The Wnt-Frizzled structure indicated that Wnts utilize a post-translational lipid modification to directly engage the Frizzled extracellular domain, which represents a highly unusual binding mode among soluble ligands. Garcia's study revealed a striking, donut-shaped architecture adopted by the Wnt-Frizzled complex that adorns the cover of the July 6th, 2012 issue of Science. More recently, Garcia's laboratory reported a breakthrough in being able to recapitulate canonical Wnt signaling using water-soluble bispecific ligands that dimerize Frizzled and Lrp6, which has important implications for the development of therapeutics for regenerative medicine.
== Diuretics and masking agents == Diuretics, sometimes known as ‘water pills,’ are drugs that alter the body's fluid and salt balance, increasing urine production. They are used for the swelling and bloating of premenstrual syndrome, for treating high blood pressure, and in older people for heart failure caused by weakening of the heart's pumping mechanism. Diuretics can be used to pass a drug test because they increase the amount of urine produced by the body, thereby it dilutes any drugs in the urine which makes it harder to identify them. Examples of diuretics and masking agents are bumetanide, chlorothiazide, furosemide, hydrochlorothiazide, probenecid, spironolactone (canrenone), triameterene, and trichlormethiazide. Finasteride is not banned.
=== Estimates of numbers === Frequency and number estimates of de novo genes in various lineages vary widely and are highly dependent on methodology. Studies may identify de novo genes by phylostratigraphy/BLAST-based methods alone, or may employ a combination of computational techniques, and may or may not assess experimental evidence for expression and/or biological role. Furthermore, genome-scale analyses may consider all or most ORFs in the genome, or may instead limit their analysis to previously annotated genes. The D. melanogaster lineage is illustrative of these differing approaches. An early survey using a combination of BLAST searches performed on cDNA sequences along with manual searches and synteny information identified 72 new genes specific to D. melanogaster and 59 new genes specific to three of the four species in the D. melanogaster species complex. This report found that only 2/72 (~2.8%) of D. melanogaster-specific new genes and 7/59 (~11.9%) of new genes specific to the species complex were derived de novo, with the remainder arising via duplication/retroposition. Similarly, an analysis of 195 young (<35 million years old) D. melanogaster genes identified from syntenic alignments found that only 16 had arisen de novo. In contrast, an analysis focused on transcriptomic data from the testes of six D. melanogaster strains identified 106 fixed and 142 segregating de novo genes. For many of these, ancestral ORFs were identified but were not expressed.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.